Bristol-Myers Squibb Company
BMY Healthcare Drug Manufacturers - General NYSE
$60.10
$-0.64 (-1.05%)
Open: $60.43 | High: $60.43 | Low: $59.45 | Prev Close: Prev Close: $60.74
Market Cap: $122.39B
Volume: 5.5M | Avg: 14.1M
Last updated: March 06, 2026 at 08:00 PMInvestment Rating
Buy
Overall Score: 80/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 562
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 17.37 |
| P/B Ratio | 6.64 |
| P/S Ratio | 2.54 |
| EPS | $3.46 |
| Beta | 0.27 |
| Shares Outstanding | 2.04B |
| 52-Week High | $63.33 |
| 52-Week Low | $42.52 |
| SMA 50 | $57.43 |
| SMA 200 | $49.72 |
| Dividend Yield | 4.14% |
| Annual Dividend | $2.49 |
| Next Earnings | April 30, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 67.6% |
| Operating Margin | 26.3% |
| Net Margin | 14.6% |
| ROE | 39.3% |
| ROA | 7.8% |
| Debt/Equity | 2.55 |
| Current Ratio | 1.26 |
| Quick Ratio | 1.14 |
Balance Sheet
| Total Assets | $90.04B |
| Total Liabilities | $71.53B |
| Total Equity | $18.47B |
|
|
|
| Cash | $10.21B |
| Total Debt | $47.14B |
| Net Debt | $36.93B |
Income Statement
| Revenue | $48.19B |
| Gross Profit | $32.60B |
| Operating Income | $12.70B |
| Net Income | $7.05B |
|
|
|
| EBITDA | $14.54B |
| Revenue/Share | $23.61 |
Cash Flow
| Operating CF | $14.16B |
| CapEx | $1.31B |
| Free Cash Flow | $12.85B |
|
|
|
| Book Value/Share | $9.07 |
| Tangible Book/Share | $-11.07 |
| Equity/Share | $9.05 |
Technical Indicators
| RSI (14) | 46.35 Neutral |
| MACD |
1.15
Signal: 1.42
|
| Volatility | 23.51% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +27.28% |
| Sharpe Ratio | 1.04 Good |
| Volatility (Ann.) | 26.5% Moderate |
| BMY (1Y) | +27.28% |
| S&P 500 (1Y) | +14.41% |
| Alpha (Excess Return) | +12.87% |
Sector Comparison (Healthcare)
| Metric | BMY | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 17.37 | 26.42 | 26% |
| P/B Ratio | 6.64 | -21.15 | 76% |
| ROE (%) | 39.27% | -10.69% | 88% |
| Net Margin (%) | 14.63% | 9.34% | 60% |
| Stock Score | 562 | 539.0 | 52% |
| 1Y Return (%) | +27.28 % | +4.68 % | 82% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | $60.10 | $61.43 | $61.45 | $61.12 | $57.56 | $49.79 | 46.35 | 1.15 | 23.51% | 5454413 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the BMY stock
News Sentiment
| Ticker | Headline | Sentiment | Source | URL |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb: 'Strong Buy' As 2026 Milestones Could Bolster Its Prospects | Neutral | seekingalpha.com | Read More |
| BMY | Bristol Myers Squibb: Low Volatility Meets High Dividend Yield | Neutral | fool.com | Read More |
| BMY | Advisors Capital Management LLC Raises Stake in Bristol Myers Squibb Company $BMY | Neutral | defenseworld.net | Read More |
| BMY | 3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery | Neutral | fool.com | Read More |
| BMY | Dividend Champion, Contender, And Challenger Highlights: Week Of April 26 | Neutral | seekingalpha.com | Read More |
Recent Insider Trading
No recent insider trading data available for BMY
Company Information
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
| CEO | Christopher S. Boerner |
| Employees | 34100 |
| Country | US |
| IPO Date | 1972-06-01 |
| Exchange | NYSE |
| Website | https://www.bms.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category